A citation-based method for searching scientific literature


List of co-cited articles
141 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
47

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
849
38

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
28

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
23

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
K Metcalfe, S Gershman, H T Lynch, P Ghadirian, N Tung, C Kim-Sing, O I Olopade, S Domchek, J McLennan, A Eisen,[...]. Br J Cancer 2011
120
23

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Lori J Pierce, Kelly-Anne Phillips, Kent A Griffith, Saundra Buys, David K Gaffney, Meena S Moran, Bruce G Haffty, Merav Ben-David, Bella Kaufman, Judy E Garber,[...]. Breast Cancer Res Treat 2010
101
23

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
359
23


Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
L C Hartmann, D J Schaid, J E Woods, T P Crotty, J L Myers, P G Arnold, P M Petty, T A Sellers, J L Johnson, S K McDonnell,[...]. N Engl J Med 1999
919
19

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
19

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
706
19

Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
Ellen Warner, Kimberley Hill, Petrina Causer, Donald Plewes, Roberta Jong, Martin Yaffe, William D Foulkes, Parviz Ghadirian, Henry Lynch, Fergus Couch,[...]. J Clin Oncol 2011
157
19

Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.
Bronson D Riley, Julie O Culver, Cécile Skrzynia, Leigha A Senter, June A Peters, Josephine W Costalas, Faith Callif-Daley, Sherry C Grumet, Katherine S Hunt, Rebecca S Nagy,[...]. J Genet Couns 2012
187
19

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
Mark E Robson, Courtney D Storm, Jeffrey Weitzel, Dana S Wollins, Kenneth Offit. J Clin Oncol 2010
298
19

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
19

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H Meijers-Heijboer, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer,[...]. N Engl J Med 2001
632
19

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Chanita Hughes Halbert, Tiffani DeMarco, William Lawrence, David Main, Clinton Finch, Colette Magnant,[...]. J Clin Oncol 2004
190
14


Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing.
Bettina Meiser, Margaret Gleeson, Kaaren Watts, Michelle Peate, Elvira Zilliacus, Kristine Barlow-Stewart, Christobel Saunders, Gillian Mitchell, Judy Kirk. Oncol Nurs Forum 2012
22
14

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Amy Finch, Mario Beiner, Jan Lubinski, Henry T Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D Foulkes,[...]. JAMA 2006
394
14

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff,[...]. N Engl J Med 2002
14

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
868
14

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose,[...]. J Med Genet 2008
127
14

Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Lori J Pierce, Albert M Levin, Timothy R Rebbeck, Merav A Ben-David, Eitan Friedman, Lawrence J Solin, Eleanor E Harris, David K Gaffney, Bruce G Haffty, Laura A Dawson,[...]. J Clin Oncol 2006
204
14

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
T C van Sprundel, M K Schmidt, M A Rookus, R Brohet, C J van Asperen, E J Th Rutgers, L J Van't Veer, R A E M Tollenaar. Br J Cancer 2005
178
14


Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Monika K Graeser, Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G Froster, Bettina Schlehe, Astrid Bechtold, Norbert Arnold,[...]. J Clin Oncol 2009
190
14

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
505
14

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H A Risch, J R McLaughlin, D E Cole, B Rosen, L Bradley, E Kwan, E Jack, D J Vesprini, G Kuperstein, J L Abrahamson,[...]. Am J Hum Genet 2001
718
14

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
Allison W Kurian, Bronislava M Sigal, Sylvia K Plevritis. J Clin Oncol 2010
155
14


Online tool to guide decisions for BRCA1/2 mutation carriers.
Allison W Kurian, Diego F Munoz, Peter Rust, Elizabeth A Schackmann, Michael Smith, Lauren Clarke, Meredith A Mills, Sylvia K Plevritis. J Clin Oncol 2012
57
14

Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.
Jeffrey N Weitzel, Kathleen R Blazer, Deborah J MacDonald, Julie O Culver, Kenneth Offit. CA Cancer J Clin 2011
146
14

Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy.
M H Frost, D J Schaid, T A Sellers, J M Slezak, P G Arnold, J E Woods, P M Petty, J L Johnson, D L Sitta, S K McDonnell,[...]. JAMA 2000
211
14

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
340
14

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
S A Narod, H Risch, R Moslehi, A Dørum, S Neuhausen, H Olsson, D Provencher, P Radice, G Evans, S Bishop,[...]. N Engl J Med 1998
384
14

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J Boyd, Y Sonoda, M G Federici, F Bogomolniy, E Rhei, D L Maresco, P E Saigo, L A Almadrones, R R Barakat, C L Brown,[...]. JAMA 2000
380
14

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
328
14

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Ivo Olivotto, Ellen Warner, Olufunmilayo I Olopade, Andrea Eisen, Barbara Weber, Jane McLennan,[...]. J Clin Oncol 2004
420
14

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
146
14

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
651
14

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
14

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion Kiechle, Nina Ditsch, Wolfgang Janni, Christoph Mundhenke, Michael Golatta,[...]. Breast Cancer Res 2012
58
14

Genetic testing and cancer risk management recommendations by physicians for at-risk relatives.
Sharon E Plon, H Paul Cooper, Bethany Parks, Shweta U Dhar, P Adam Kelly, Armin D Weinberg, Stephanie Staggs, Tao Wang, Susan Hilsenbeck. Genet Med 2011
77
9



Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Victor R Grann, Priya R Patel, Judith S Jacobson, Ellen Warner, Daniel F Heitjan, Maxine Ashby-Thompson, Dawn L Hershman, Alfred I Neugut. Breast Cancer Res Treat 2011
69
9


Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
S K McDonnell, D J Schaid, J L Myers, C S Grant, J H Donohue, J E Woods, M H Frost, J L Johnson, D L Sitta, J M Slezak,[...]. J Clin Oncol 2001
190
9

Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
Kenneth P Tercyak, Beth N Peshkin, Barbara M Brogan, Tiffani DeMarco, Marie F Pennanen, Shawna C Willey, Colette M Magnant, Sarah Rogers, Claudine Isaacs, Marc D Schwartz. J Clin Oncol 2007
57
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.